MARKET

IBRX

IBRX

Immunitybio Inc
NASDAQ
6.23
+0.40
+6.86%
After Hours: 6.25 +0.02 +0.32% 19:59 06/18 EDT
OPEN
5.84
PREV CLOSE
5.83
HIGH
6.35
LOW
5.80
VOLUME
2.66M
TURNOVER
0
52 WEEK HIGH
10.53
52 WEEK LOW
1.250
MARKET CAP
4.31B
P/E (TTM)
-5.9058
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IBRX last week (0610-0614)?
Weekly Report · 2d ago
Weekly Report: what happened at IBRX last week (0603-0607)?
Weekly Report · 06/10 09:05
IMMUNITYBIO ANNOUNCES 2024 ANNUAL MEETING OF STOCKHOLDERS WITH COMPANY UPDATE
Reuters · 06/07 13:13
ImmunityBio: Anktiva's Launch Demands A Reassessment
ImmunityBio's flagship product, Anktiva, has been launched in the market for the treatment of bladder cancer. The company is a biotech that develops and commercializes therapies designed to boost the body's immune system to destroy cancers and infectious diseases. I believe it is time to reassess my IBRX strategy for ImmunityBio (NASDAQ:IBRX) I provide a brief background on ImmunityBio and its flagship product. I also provide my views on Anktivan's launch and what investors should watch for in the next quarter.
Seeking Alpha · 06/06 19:09
ImmunityBio, LadRx end licensing deal for cancer drug
Healthcare ImmunityBio, LadRx end licensing deal for cancer drug for aldoxorubicin. The drug is an investigational therapy targeted at soft tissue sarcoma and other cancers. XOMA Corporation and ImmunityBio revise their 2023 royalty agreement related to the drug.
Seeking Alpha · 06/04 11:06
LadRx And ImmunityBio Agree To Terminate Aldoxorubicin License
NASDAQ · 06/04 01:39
Weekly Report: what happened at IBRX last week (0527-0531)?
Weekly Report · 06/03 09:06
Weekly Report: what happened at IBRX last week (0520-0524)?
Weekly Report · 05/27 09:06
More
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

Webull offers Immunitybio Inc stock information, including NASDAQ: IBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IBRX stock methods without spending real money on the virtual paper trading platform.